Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | BCAT1 | P54687 | 4/20 | 0.56 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | GUSB | P08236 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398132 | 0.88 | MAPT (0.68) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6404723 | 0.87 | NHERF1 (0.62) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6400591 | 0.85 | GUSB (0.61) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6399657 | 0.82 | NHERF1 (0.58) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6407379 | 0.82 | BCAT1 (0.67) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6405713 | 0.80 | MAPT (0.70) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL4938637 | 0.80 | MAPT (0.58) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6406653 | 0.80 | MEN1 (0.75) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6400859 | 0.80 | PYGL (0.56) | MAPTBCAT1NHERF1MEN1KMT2A | |
| SCHEMBL6400655 | 0.79 | NHERF1 (0.69) | MAPTBCAT1NHERF1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | MAPT 4405/4885BCAT1 854/4885NHERF1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.